Rocket Pharmaceuticals Inc. (RCKT)

The total asset value of Rocket Pharmaceuticals Inc (RCKT) stood at $ 528 Mln as on 31-Dec-24

The share price of Rocket Pharmaceuticals Inc (RCKT) is $7.14 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Rocket Pharmaceuticals Inc (RCKT) has given a return of -16.51% in the last 3 years.

Rocket Pharmaceuticals Inc (RCKT) has a market capitalisation of $ 765 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.

Since, TTM earnings of Rocket Pharmaceuticals Inc (RCKT) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Rocket Pharmaceuticals Inc (RCKT) and enter the required number of quantities and click on buy to purchase the shares of Rocket Pharmaceuticals Inc (RCKT).

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. Address: 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512

The CEO & director of Dr. Gaurav D. Shah M.D.. is Rocket Pharmaceuticals Inc (RCKT), and CFO & Sr. VP is Dr. Gaurav D. Shah M.D..

There is no promoter pledging in Rocket Pharmaceuticals Inc (RCKT).

Some of the close peers are:

No, TTM profit after tax of Rocket Pharmaceuticals Inc (RCKT) was $0 Mln.